U.S. Markets closed

Free Research Reports on Catalent and Three More Generic Drugs Stocks

Stock Research Monitor: CPRX, COLL, and DPLO

LONDON, UK / ACCESSWIRE / June 28, 2018 / If you want a free Stock Review on CTLT sign up now at www.wallstequities.com/registration. Today, WallStEquities.com takes a close look at the following Generic Drugs stocks: Catalent Inc. (NYSE: CTLT), Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX), Collegium Pharmaceutical Inc. (NASDAQ: COLL), and Diplomat Pharmacy Inc. (NYSE: DPLO). Generic pharmaceutical and medicine manufacturers develop prescription and over-the-counter drug products that are used to prevent or treat illnesses in humans or animals. Generic drugs are produced and distributed without patent protection, and industry operators are not significantly engaged in the research and development of new drugs.All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Catalent

On Wednesday, shares in Somerset, New Jersey headquartered Catalent Inc. recorded a trading volume of 949,998 shares. The stock ended the session 1.44% lower at $41.09. The Company's shares have gained 6.12% in the last month, 1.38% over the previous three months, and 14.87% over the past year. The stock is trading 1.59% above its 50-day moving average. Moreover, shares of Catalent, which provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide, have a Relative Strength Index (RSI) of 51.97. Get the full research report on CTLT for free by clicking below at:

www.wallstequities.com/registration/?symbol=CTLT


Catalyst Pharmaceuticals

Coral Gables, Florida-based Catalyst Pharmaceuticals Inc.'s stock closed the day 1.57% lower at $3.13 with a total trading volume of 712,313 shares. The Company's shares have advanced 24.70% in the previous three months and 14.23% over the past year. The stock is trading 0.67% below its 50-day moving average. Additionally, shares of Catalyst Pharma, which focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, have an RSI of 42.74.

On June 13th, 2018, Catalyst Pharma announced the appointment of Daniel J. Brennan as Chief Commercial Officer. Mr. Brennan will be responsible for leading the Company's marketing, sales, and commercial operations as it prepares for a potential launch of Firdapse®. Today's complimentary research report on CPRX is accessible at:


www.wallstequities.com/registration/?symbol=CPRX


Collegium Pharmaceutical

Shares in Canton, Massachusetts headquartered Collegium Pharmaceutical Inc. recorded a trading volume of 402,167 shares. The stock ended yesterday's trading session 3.91% lower at $24.79. The Company's shares have advanced 5.31% in the past month and 100.57% over the past year. The stock is trading above its 200-day moving average by 23.60%. Furthermore, shares of Collegium Pharma, which develops and commercializes various products for patients suffering from pain, have an RSI of 45.99.

On June 04th, 2018, Collegium Pharma announced that Joseph Ciaffoni, Executive Vice President and COO, will be promoted to CEO and join the Board of Directors, effective July 01st, 2018. Mr. Ciaffoni will succeed Michael T. Heffernan, who will step down as CEO on June 30th, 2018. Mr. Heffernan will continue to serve as Chairman of the Board, and in that capacity, will continue to advise on the Company's strategic initiatives following the succession. Sign up for free on Wall St. Equities and claim the latest report on COLL at:

www.wallstequities.com/registration/?symbol=COLL

Diplomat Pharmacy

Flint, Michigan headquartered Diplomat Pharmacy Inc.'s stock finished Wednesday's session 0.70% higher at $27.32 with a total trading volume of 425,210 shares. The Company's shares have advanced 13.03% in the last month, 32.94% over the previous three months, and 78.56% over the past year. The stock is trading above its 50-day and 200-day moving averages by 14.21% and 24.81%, respectively. Additionally, shares of Diplomat Pharmacy, which operates as an independent specialty pharmacy in the US, have an RSI of 62.32.

On June 05th, 2018, Diplomat Pharmacy announced that the Compensation Committee of its Board of Directors has made certain equity awards to new CEOBrian Griffin, effectiveJune 04th, 2018.The awards were made pursuant to the Company's previously announced employment agreement with Mr. Griffin, and as a material inducement to his joining as CEO and Chairman of the Board. See the free research coverage on DPLO at:

www.wallstequities.com/registration/?symbol=DPLO

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities